# Pulsify Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulsify-medical

- Industry: Medical Devices & Equipment
- Headquarters: Leuven, Belgium
- Website: www.pulsify-medical.com
- Total disclosed funding: $2.9M
- Latest round: Seed (Oct 4, 2019)
- Investors on record: 2

## About

Pulsify Medical develops innovative cardiac monitoring technologies, centered around the Pulsify Patch, which utilizes non-invasive ultrasound sensors to continuously track cardiac performance, enhancing patient care in healthcare settings.Founded in 2019 in Leuven, Belgium, Pulsify Medical focuses on advanced cardiac monitoring solutions. The company has raised EUR 2.6 million in a SEED funding round led by Imec.xpand and K.U. Leuven Research & Development. Xavier Rottenberg is the founder, who has a background in medical technology ventures.Pulsify Medical specializes in innovative cardiac monitoring technology, with its flagship product being the Pulsify Patch. This device is designed to continuously and directly monitor cardiac performance using a non-invasive ultrasound sensor. The patch can be comfortably worn on the chest for extended periods, providing critical data on cardiac output, stroke volume, and left ventricular ejection fraction. The primary use cases for the Pulsify Patch involve patients with cardiovascular diseases and other related conditions who require consistent monitoring of their cardiac function. The technology aims to enhance clinical decision-making and improve patient risk management in intensive care settings. Pulsify's products primarily target healthcare facilities, including hospitals and intensive care units, across European markets, with a focus on regions that prioritize advanced cardiac care.Pulsify Medical's revenue model is structured around B2B transactions with healthcare institutions, wherein hospitals and clinics acquire the Pulsify Patch and associated monitoring services. The company engages in partnerships with medical providers to facilitate the distribution and integration of their technology into clinical workflows. Revenue is generated through direct sales of the Pulsify Patch, potentially accompanied by ongoing service agreements that include data analytics and monitoring support. Specific pricing plans for the products have not been disclosed, but the business framework suggests a model that could involve bulk purchasing agreements or subscription-based analytics services that enhance the value of the monitoring technology for end-users. In 2023, the EBITDA reported was EUR 97,708.90.Pulsify Medical plans to expand its product offerings with the introduction of updated versions of the Pulsify Patch, aiming for a release within the next 12 months. The company is exploring opportunities to enter new European markets, particularly targeting Germany and France, by the end of 2024. The recent funding of EUR 2.6 million raised in October 2019 will support the development of new products and market entry strategies.

## Funding rounds

- Seed, Oct 4, 2019, $2.9M — K.U. Leuven Research & Development, Imec.xpand

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Seed
- Imec.xpand (https://capitalatlas.ai/funds/imec-xpand) — Seed